Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

About this resource:

HHS Non-systematic Review

Source: National Institutes of Health

Last Reviewed: February 2021

Workgroups: HIV Workgroup

In this report, the Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission provides recommendations on antiretroviral treatment (ART) in pregnancy. Since some ART drugs have not been sufficiently studied for evidence of harm to mothers and infants, the panel uses a graded approach to recommendations — noting, for example, when there is insufficient data to recommend a medicine for pregnant people. In the latest version of the recommendations, the panel added a section on pre-exposure prophylaxis and began addressing the care of transgender and non-binary people who are pregnant or trying to get pregnant.

Read more about this resource

Objectives related to this resource (1)

Suggested Citation

1.

U.S. Department of Health and Human Services, Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. (2021). Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. Retrieved from https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines